JINXIA CHEN1,2,3,#, SULI DAI1,2,#, GENG ZHANG4,5, SISI WEI1,2, XUETAO ZHAO3, YANG ZHENG1,2, YAOJIE WANG1,2, XIAOHAN WANG1,2, YUNJIANG LIU4,5,*, LIANMEI ZHAO1,2,*
Oncology Research, Vol.32, No.11, pp. 1791-1802, 2024, DOI:10.32604/or.2024.049348
- 16 October 2024
Abstract Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC.… More >
Graphic Abstract
Login
Register
